PA46s: Summary of Gross Pathology Test Compound: Benzo(a)pyrene CAS Number: 50-32-8

Study Number:	110353
Study Gender:	Female
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.3.2
Stat Version:	v2.7.2A

Female: Immunopath										
	Treatment Groups (mg/kg)									
	0	2	5	9	19	38	75	150	50 mg/kg CPS	
Disposition Summary										
Animals Initially In Study	8	8	8	8	8	8	8	8	8	
Censored										
Early Deaths										
Survivors										
Scheduled Sacrifice, Terminal	8	8	8	8	8	8	8	8	8	
Number of Animals Examined	8	8	8	8	8	8	8	8	8	
ALIMENTARY SYSTEM				· · ·						
STOMACH, FORESTOMACH	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
THICK; MODERATE	1 (12.5%)									
CARDIOVASCULAR SYSTEM										
None										
ENDOCRINE SYSTEM										
None										
GENERAL BODY SYSTEM										
None										

PA46s: Summary of Gross Pathology Test Compound: Benzo(a)pyrene CAS Number: 50-32-8

Date Report Requested: 09/16/2021 Time Report Requested: 12:41:43 Lab: BRT with ILS

	Female: Immunopath									
	Treatment Groups (mg/kg)									
	0	2	5	9	19	38	75	150	50 mg/kg CPS	
GENITAL SYSTEM										
OVARY, LEFT	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
SMALL; MARKED	0 **						2 (25.0%)	5 (62.5%) *		
SMALL; MILD	1 (12.5%)							1 (12.5%)		
SMALL; MODERATE	0 **							2 (25.0%)		
OVARY, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
SMALL; MARKED	0 **						2 (25.0%)	5 (62.5%) *		
SMALL; MILD	1 (12.5%)							1 (12.5%)		
SMALL; MODERATE	0 **							2 (25.0%)		
UTERUS	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(0)	
SMALL; MARKED	0 *						1 (12.5%)	1 (12.5%)		
SMALL; MODERATE	0 **						1 (12.5%)	2 (25.0%)		
HEMATOLYMPHOID SYSTEM										
SPLEEN	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
DISCOLORATION; DARK	1 (12.5%)									
DISCOLORATION; DARK, MODERATE			1 (12.5%)							
SMALL; MILD	1 (12.5%) **	1 (12.5%)	1 (12.5%)	1 (12.5%)		2 (25.0%)	3 (37.5%)	5 (62.5%)	6 (75.0%) [•]	
SMALL; MODERATE								1 (12.5%)	1 (12.5%)	
THYMUS	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
SMALL; MARKED	0 **							4 (50.0%) *	4 (50.0%)	
SMALL; MODERATE	0 **	1 (12.5%)			1 (12.5%)	2 (25.0%)	6 (75.0%) **	4 (50.0%) *	4 (50.0%)	

MUSCULOSKELETAL SYSTEM

None

Female: Immunopath										
	Treatment Groups (mg/kg)									
	0	2	5	9	19	38	75	150	50 mg/kg CPS	
NERVOUS SYSTEM None										
RESPIRATORY SYSTEM				· · · ·			· · · · · ·			
LUNG	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	
DISCOLORATION; MARKED, MOTTLED							1 (12.5%)			
DISCOLORATION; MILD, RED	1 (12.5%)			1 (12.5%)		1 (12.5%)				
DISCOLORATION; MODERATE, RED				3 (37.5%)		1 (12.5%)	1 (12.5%)			
THORAX	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(0)	
ADHESION; MODERATE		1 (12.5%)								
SPECIAL SENSES SYSTEM										
None										
URINARY SYSTEM										
KIDNEY, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(8)	(0)	
CYST			1 (12.5%)	1 (12.5%)						

			Female	SRBC						
	Treatment Groups (mg/kg)									
	0	2	5	9	19	38	75	150	50 mg/kg CPS	
Disposition Summary										
Animals Initially In Study	8	8	8	8	8	8	8	8	8	
Censored										
Early Deaths										
Survivors										
Scheduled Sacrifice, Terminal	8	8	8	8	8	8	8	8	8	
Number of Animals Examined	8	8	8	8	8	8	8	8	8	
ALIMENTARY SYSTEM										
None										
CARDIOVASCULAR SYSTEM										
None										
ENDOCRINE SYSTEM										
None										
GENERAL BODY SYSTEM										
None										
GENITAL SYSTEM										
None										

PA46s: Summary of Gross Pathology Test Compound: Benzo(a)pyrene CAS Number: 50-32-8

			Femal	e: SRBC						
	Treatment Groups (mg/kg)									
	0	2	5	9	19	38	75	150	50 mg/kg CPS	
HEMATOLYMPHOID SYSTEM										
SPLEEN ENLARGED	(8)	(8)	(8)	(8)	(8)	(8) 1 (12.5%)	(8)	(8)	(8)	
SMALL; MARKED SMALL	0 **			1 (12.5%)		2 (25.0%)	5 (62.5%) *	1 (12.5%) 6 (75.0%) **	3 (37.5%) 5 (62.5%) *	
THYMUS SMALL; MARKED	(8) 0	(8)	(8)	(8)	(8)	(8)	(8)	(8) 1 (12.5%)	(8) 5 (62.5%) *	
SMALL	0 **				1 (12.5%)	1 (12.5%)	1 (12.5%)	6 (75.0%) **	3 (37.5%)	
INTEGUMENTARY SYSTEM None										
MUSCULOSKELETAL SYSTEM None										
NERVOUS SYSTEM None										
RESPIRATORY SYSTEM None										
SPECIAL SENSES SYSTEM None										
URINARY SYSTEM None						-		-		

Date Report Requested: 09/16/2021 Time Report Requested: 12:41:43 Lab: BRT with ILS

LEGEND

Censored animals are scheduled for sacrifice prior to the end of the study. The censored animals are included in the pathology data.

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number (percent) of animals affected given for each observation

Statistical analysis performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) one-sided tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Fisher Exact test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

CPS = Cyclophosphamide

** END OF REPORT **